While changes to Lilly’s portfolio have played a role in year-over-year discounts, further increases in competition among pharmaceutical manufacturers and increased negotiation leverage by pharmacy-benefit managers (PBMs) have resulted in consistently deeper discretionary discounting over the last several years.